Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,492.17% | -79.84% | 1,684.38% | 132.21% | 79.09% |
| Total Depreciation and Amortization | 0.00% | 0.41% | 0.25% | 0.79% | 0.67% |
| Total Amortization of Deferred Charges | 2.02% | 2.66% | 2.73% | 2.80% | -2.84% |
| Total Other Non-Cash Items | 910.82% | -21.47% | -31.02% | 52.62% | 12.72% |
| Change in Net Operating Assets | -994.69% | -61.66% | -106.08% | 189.16% | 25.53% |
| Cash from Operations | -16.28% | -50.76% | 8.74% | 10,027.47% | 101.81% |
| Capital Expenditure | 35.69% | 2.40% | -369.01% | 74.55% | -2,046.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 35.69% | 2.40% | -369.01% | 74.55% | -2,046.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.91% | 542.07% | -91.11% | 695.12% | -62.93% |
| Repurchase of Common Stock | 98.88% | -1,005.00% | -222.18% | 44.42% | 89.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 121.99% | -3,222.18% | -101.92% | 1,370.28% | 130.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,312.01% | -96.36% | -39.64% | 3,711.95% | 106.41% |